Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
December 30, 2022
Beijing, China, December 30, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the third member of the RenMiceTM family, joining RenMabTM and RenLite®. Together, Biocytogen’s three RenMiceTM platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies) (Figure […]
7th Tumor Models for Immuno-Oncology Summit
December 27, 2022
Join us at the 7th Tumor Models for Immuno-Oncology Summit in San Francisco, CA from January 24 – 26, 2023! We will be presenting “Next-Generation Mouse Models to Evaluate Efficacy of Novel Antibody and Cell-Based Immunotherapies” at 10:15AM PST on Thursday, Jan. 26. Speaker Session: Thursday, Jan. 26, 10:15AM PST Speaker: Jenna Frame, Ph.D. Manager, […]
Biocytogen BDL Team to Participate in the 41st Annual JPM Healthcare Conference, the Biotech Showcase and BIO Partnering at JPM
December 21, 2022
Biocytogen (HKEX: 02315) will attend the upcoming 41st J.P. Morgan (JPM) Healthcare Conference week, and participate in several satellite conferences, including the Biotech Showcase and BIO Partnering at JPM, which are all to be held in San Francisco from January 9-12, 2023. The team will also present in the BFC conference and ACCESS CHINA before […]
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
December 19, 2022
BEIJING, China, December 19, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb). The IND application was completed by Biocytogen’s wholly owned subsidiary […]
American Society for Cell Biology 2022
November 29, 2022
Join us at booth #704 at Cell Bio 2022 from December 3-7 in Washington, DC, hosted by American Society for Cell Biology (ASCB)! Whether you need humanized models, PK/PD services, or antibody discovery services, we’d love to partner with you to evaluate your novel immunotherapies. We have extensive experience testing novel monoclonal antibodies, bispecific antibodies, and […]
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
November 28, 2022
BEIJING, China, November 28, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a […]
Antibody Engineering & Therapeutics 2022
November 22, 2022
Join us at booth #608 at Antibody Engineering & Therapeutics 2022 in San Diego, CA, December 4 – 8! Learn more about our antibody discovery capabilities and humanized antibody mice. Our Beacon- and FACS-based screening services can identify hundreds, or even thousands, of single B cells that generate antibodies to your target in one day, […]
First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients
November 21, 2022
Beijing, China and San Diego, CA, November 21, 2022 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced dosing of the first patient in a Phase 1/2 Trial that studies its CTLA-4 antibody YH001 in combination […]
BioMice’s Target Humanized Mouse Models Enable Preclinical Toxicity Studies to Support IND Approval
November 10, 2022
In February 2022, to meet the challenge of NHP shortage, the Food and Drug Administration (FDA) published a new guideline – Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic: Guidance for Industry. To quote, “although the stated preference of ICH S6(R1)8 is for testing the clinical candidate (in the NHP), […]
Neuroscience 2022
November 8, 2022
Join us at booth #2703 at Neuroscience 2022 in San Diego, CA, November 12-16! Learn more about our latest model and service offerings. Whether you need humanized or custom models, pharmacology services, or antibody discovery assistance, we’d love to partner with you! Each year, scientists from around the world congregate to discover new ideas, share […]
